Werewolf Therapeutics IPO priced at $16/share (update)

• Update 10:21pm: Adds company confirmation.
• Werewolf Therapeutics (NASDAQ:HOWL) priced its IPO at $16/share.
• Werewolf Therapeutics is selling 7.5M shares, upsized from 6.25M at $16/share. The pricing is at midpoint of expected range.
• The company expects to receive about $120M in gross proceeds from the offering, according to a statement. The shares are expected to begin trading on the Nasdaq tomorrow under the ticker symbol “HOWL."
• Werewolf is developing conditionally activated anti-cancer drugs called pro-inflammatory immunomodulators, or what the company refers to “indukine" molecules.
• Werewolf has three early stage drugs the furthest along in its pipeline, including its lead candidate, WTX-124. That’s designed to treat advanced solid tumors.
• Jefferies, SVB Leerink and Evercore ISI are acting as joint book-running managers for the offering. H.C. Wainwright is acting as lead manager for the offering.
• The news was earlier reported by IPO Boutique.
• See SA author Donovan Jones piece entitled "IPO Update: Werewolf Therapeutics Finalizes IPO Plan."